Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239629 | 0.82 | SCN10A (0.38) | SCN10AKMT2AMPO | |
| SCHEMBL20639342 | 0.82 | SCN10A (0.38) | SCN10AKMT2AMPO | |
| SCHEMBL12470342 | 0.81 | SCN10A (0.39) | SCN10AKMT2A | |
| SCHEMBL241559 | 0.80 | SCN10A (0.43) | SCN10AMPO | |
| SCHEMBL20694958 | 0.80 | SCN10A (0.43) | SCN10AMPO | |
| SCHEMBL15452940 | 0.76 | SCN10A (0.38) | SCN10A | |
| SCHEMBL238095 | 0.76 | SCN10A (0.38) | SCN10A | |
| SCHEMBL2278873 | 0.75 | SCN10A (0.38) | SCN10A | |
| SCHEMBL242122 | 0.75 | SCN10A (0.43) | SCN10A | |
| SCHEMBL236935 | 0.75 | SCN10A (0.43) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678334-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2627651-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012116257-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012051361-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-19 | — | — | WO | disclosed |